PMVP
HEALTHCAREPMV Pharmaceuticals Inc
$1.45+0.08 (+5.84%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PMVP Today?
No stock-specific AI insight has been generated for PMVP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.81$1.88
$1.45
Fundamentals
Market Cap$77M
P/E Ratio—
EPS$-1.48
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume215K
Avg Volume (10D)—
Shares Outstanding53.3M
PMVP News
19 articles- PMV Pharmaceuticals Announces Board Chair TransitionGlobeNewswire Inc.·Apr 22, 2026
- Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?Yahoo Finance·Apr 20, 2026
- PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate HighlightsYahoo Finance·Mar 6, 2026
- New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid TumorsYahoo Finance·Feb 26, 2026
- CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a TurnaroundMotley Fool·Feb 3, 2026
- Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.Motley Fool·Feb 3, 2026
- Caesarstone And 2 More Penny Stocks Worth WatchingYahoo Finance·Jan 29, 2026
- Top Penny Stocks To Watch In November 2025Yahoo Finance·Nov 18, 2025
- PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate HighlightsYahoo Finance·Nov 12, 2025
- Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Oct 28, 2025
- PMV Pharmaceuticals Says Updated Rezatapopt Data Show 46% Response Rate in Ovarian CancerYahoo Finance·Oct 24, 2025
- PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C MutationYahoo Finance·Oct 24, 2025
- PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 13, 2025
- Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor TypesYahoo Finance·Sep 10, 2025
- PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C MutationYahoo Finance·Sep 10, 2025
- PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate HighlightsYahoo Finance·Aug 7, 2025
- PMV Pharmaceuticals to Participate at Upcoming Investor ConferencesYahoo Finance·May 23, 2025
- We're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn RateYahoo Finance·May 18, 2025
- PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsYahoo Finance·May 9, 2025
All 19 articles loaded
Price Data
Open$1.39
Previous Close$1.37
Day High$1.46
Day Low$1.39
52 Week High$1.88
52 Week Low$0.81
52-Week Range
$0.81$1.88
$1.45
Fundamentals
Market Cap$77M
P/E Ratio—
EPS$-1.48
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume215K
Avg Volume (10D)—
Shares Outstanding53.3M
About PMV Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53 mutations in cancer. The company is headquartered in Cranbury, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—